{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:57:55Z","timestamp":1792252675417,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00296-020-04705-2","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T11:03:38Z","timestamp":1600859018000},"page":"2039-2046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Utility of the neutrophil-to-lymphocyte ratio for predicting bacterial infection in patients with rheumatoid arthritis receiving Tocilizumab"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-8933","authenticated-orcid":false,"given":"Yoshiki","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-443X","authenticated-orcid":false,"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Sugii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"10055","key":"4705_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/s0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet (London, England) 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/s0140-6736(16)30173-8","journal-title":"Lancet (London, England)"},{"issue":"5","key":"4705_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.080791","volume":"36","author":"T Koike","year":"2009","unstructured":"Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36(5):898\u2013906. https:\/\/doi.org\/10.3899\/jrheum.080791","journal-title":"J Rheumatol"},{"issue":"9990","key":"4705_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/s0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (London, England) 386(9990):258\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(14)61704-9","journal-title":"Lancet (London, England)"},{"issue":"19","key":"4705_CR4","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275\u20132285. https:\/\/doi.org\/10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"issue":"4","key":"4705_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of Tocilizumab in giant-cell arteritis. New Engl J Med 377(4):317\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1613849","journal-title":"New Engl J Med"},{"issue":"12","key":"4705_CR6","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T (2018) Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720\u20131729. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"issue":"9617","key":"4705_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (London, England) 371(9617):987\u2013997. https:\/\/doi.org\/10.1016\/s0140-6736(08)60453-5","journal-title":"Lancet (London, England)"},{"issue":"12","key":"4705_CR8","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70(12):2148\u20132151. https:\/\/doi.org\/10.1136\/ard.2011.151092","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4705_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10165-008-0111-7","volume":"19","author":"H Fujiwara","year":"2009","unstructured":"Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M (2009) Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 19(1):64\u201368. https:\/\/doi.org\/10.1007\/s10165-008-0111-7","journal-title":"Mod Rheumatol"},{"key":"4705_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-010423","author":"SF Bari","year":"2013","unstructured":"Bari SF, Khan A, Lawson T (2013) C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2013-010423","journal-title":"BMJ Case Rep"},{"issue":"10","key":"4705_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/1756-185x.13157","volume":"20","author":"S Chandrashekara","year":"2017","unstructured":"Chandrashekara S, Mukhtar Ahmad M, Renuka P, Anupama KR, Renuka K (2017) Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis. Int J Rheumatic Dis 20(10):1457\u20131467. https:\/\/doi.org\/10.1111\/1756-185x.13157","journal-title":"Int J Rheumatic Dis"},{"issue":"3","key":"4705_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/14397595.2016.1214340","volume":"27","author":"B Ghang","year":"2017","unstructured":"Ghang B, Kwon O, Hong S, Lee CK, Yoo B, Kim YG (2017) Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Mod Rheumatol 27(3):405\u2013410. https:\/\/doi.org\/10.1080\/14397595.2016.1214340","journal-title":"Mod Rheumatol"},{"issue":"3","key":"4705_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1272\/jnms.83.118","volume":"83","author":"M Koiwa","year":"2016","unstructured":"Koiwa M, Goto S, Takahashi K, Kamada T, Takai S, Nakamura H (2016) Neutrophil\/lymphocyte ratio inpatients with rheumatoid arthriti. J Nippon Medical School = Nippon Ika Daigaku zasshi 83(3):118\u2013124. https:\/\/doi.org\/10.1272\/jnms.83.118","journal-title":"J Nippon Medical School = Nippon Ika Daigaku zasshi"},{"issue":"7","key":"4705_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/1756-185x.12582","volume":"18","author":"AU Uslu","year":"2015","unstructured":"Uslu AU, Kucuk A, Sahin A, Ugan Y, Yilmaz R, Gungor T, Bagcaci S, Kucuksen S (2015) Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheumatic Dis 18(7):731\u2013735. https:\/\/doi.org\/10.1111\/1756-185x.12582","journal-title":"Int J Rheumatic Dis"},{"issue":"10","key":"4705_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/apm.12722","volume":"125","author":"Z Yang","year":"2017","unstructured":"Yang Z, Zhang Z, Lin F, Ren Y, Liu D, Zhong R, Liang Y (2017) Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS 125(10):863\u2013871. https:\/\/doi.org\/10.1111\/apm.12722","journal-title":"APMIS"},{"issue":"2","key":"4705_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00393-016-0187-y","volume":"77","author":"O Zengin","year":"2018","unstructured":"Zengin O, Onder ME, Kalem A, Bilici M, Turkbeyler IH, Ozturk ZA, Kisacik B, Onat AM (2018) New inflammatory markers in early rheumatoid arthritis. Z Rheumatol 77(2):144\u2013150. https:\/\/doi.org\/10.1007\/s00393-016-0187-y","journal-title":"Z Rheumatol"},{"issue":"1","key":"4705_CR17","doi-asserted-by":"publisher","first-page":"e018092","DOI":"10.1136\/bmjopen-2017-018092","volume":"8","author":"U Hamiel","year":"2018","unstructured":"Hamiel U, Bahat H, Kozer E, Hamiel Y, Ziv-Baran T, Goldman M (2018) Diagnostic markers of acute infections in infants aged 1 week to 3 months: a retrospective cohort study. BMJ Open 8(1):e018092. https:\/\/doi.org\/10.1136\/bmjopen-2017-018092","journal-title":"BMJ Open"},{"issue":"9","key":"4705_CR18","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.ijporl.2015.06.016","volume":"79","author":"T Baglam","year":"2015","unstructured":"Baglam T, Binnetoglu A, Yumusakhuylu AC, Gerin F, Demir B, Sari M (2015) Predictive value of the neutrophil-to-lymphocyte ratio in patients with deep neck space infection secondary to acute bacterial tonsillitis. Int J Pediatr Otorhinolaryngol 79(9):1421\u20131424. https:\/\/doi.org\/10.1016\/j.ijporl.2015.06.016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"4705_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4149\/BLL_2017_099","volume":"118","author":"O Kartal","year":"2017","unstructured":"Kartal O, Kartal AT (2017) Value of neutrophil to lymphocyte and platelet to lymphocyte ratios in pneumonia. Bratisl Lek Listy 118(9):513\u2013516. https:\/\/doi.org\/10.4149\/BLL_2017_099","journal-title":"Bratisl Lek Listy"},{"issue":"11","key":"4705_CR20","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s10067-017-3792-5","volume":"36","author":"HA Kim","year":"2017","unstructured":"Kim HA, Jung JY, Suh CH (2017) Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus. Clin Rheumatol 36(11):2479\u20132485. https:\/\/doi.org\/10.1007\/s10067-017-3792-5","journal-title":"Clin Rheumatol"},{"key":"4705_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.02.2012.5835","author":"Y Yanagawa","year":"2012","unstructured":"Yanagawa Y, Hirano Y, Kato H, Iba T (2012) The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr.02.2012.5835","journal-title":"BMJ Case Rep"},{"issue":"4","key":"4705_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","volume":"78","author":"A Pawar","year":"2019","unstructured":"Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC (2019) Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis 78(4):456\u2013464. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214367","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4705_CR23","first-page":"2416","volume":"33","author":"T Matsui","year":"2006","unstructured":"Matsui T, Ohsumi K, Ozawa N, Shimada K, Sumitomo S, Shimane K, Kawakami M, Nakayama H, Sugii S, Ozawa Y, Tohma S (2006) CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol 33(12):2416\u20132424","journal-title":"J Rheumatol"},{"issue":"6","key":"4705_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10165-009-0223-8","volume":"19","author":"T Matsui","year":"2009","unstructured":"Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S (2009) Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol 19(6):696\u2013697. https:\/\/doi.org\/10.1007\/s10165-009-0223-8","journal-title":"Mod Rheumatol"},{"issue":"9","key":"4705_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/INF.0b013e318295a3d0","volume":"32","author":"JT Gaensbauer","year":"2013","unstructured":"Gaensbauer JT, Press CA, Hollister JR, Asturias EJ (2013) Procalcitonin: a marker of infection not subverted by treatment with interleukin-6 receptor inhibition. Pediatr Infect Dis J 32(9):1040. https:\/\/doi.org\/10.1097\/INF.0b013e318295a3d0","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"4705_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ams2.322","volume":"5","author":"O Nishida","year":"2018","unstructured":"Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T et al (2018) The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). Acute Med Surg 5(1):3\u201389. https:\/\/doi.org\/10.1002\/ams2.322","journal-title":"Acute Med Surg"},{"issue":"4","key":"4705_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3343\/alm.2019.39.4.345","volume":"39","author":"AY Gasparyan","year":"2019","unstructured":"Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD (2019) The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med 39(4):345\u2013357. https:\/\/doi.org\/10.3343\/alm.2019.39.4.345","journal-title":"Ann Lab Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04705-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T01:00:55Z","timestamp":1632358855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04705-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4705"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04705-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Tokyo Metropolitan Tama Medical Center (30\u2013174), and the patient\u2019s written informed consent was waived by the approving IRB, as this was a retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}